Drugs / 68Ga-P15-041
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02826382 | Sep 2016 → Dec 2022 | metastatic carcinoma in the bone, prostate cancer | Five Eleven Pharma, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05627778 | Nov 2021 → Dec 2022 | metastatic prostate carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-P15-041 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05627778 ↗ |
| Modality | Diagnostic / imaging agent | “Imaging by Positron Emission Tomography” NCT02826382 ↗ |